Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE)
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Systemic lupus erythematosus (SLE) is an independent risk factor for atherosclerosis.
Endothelial dysfunction is the earliest marker of atherosclerosis and is measured by flow
mediated dilation (FMD) of the brachial artery. The purpose of the study was to measure FMD
in mild, stable SLE patients and look for change in FMD with the immunosuppressant drug
mycophenolate mofetil (MMF).
Phase:
Phase 4
Details
Lead Sponsor:
Guy's and St Thomas' NHS Foundation Trust
Collaborator:
Institute of Child Health, University College London, London, UK.